Related Experiment Videos
Making progress in early breast cancer: Taking time or accepting risk?
Gurdeep S Mannu1, David Dodwell2
1Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, United Kingdom.
European Journal of Cancer (Oxford, England : 1990)
|April 16, 2017
Summary
Improving early breast cancer outcomes relies on adjuvant therapies. However, smaller event rates necessitate larger, longer randomized controlled trials (RCTs), prompting a look at observational data and surrogate markers.
Area of Science:
- Oncology
- Clinical Trials
- Biostatistics
Background:
- Outcomes for early breast cancer patients in developed nations have significantly improved.
- Adjuvant therapies are crucial for this progress, validated by large randomized controlled trials (RCTs) and meta-analyses.
- Decreasing event rates in early breast cancer trials pose challenges, requiring larger sample sizes and longer follow-up periods.
Purpose of the Study:
- To address the challenges posed by smaller event rates in early breast cancer clinical trials.
- To evaluate the reliance on observational data and surrogate markers for determining treatment effects.
- To propose simplifications in the design and conduct of RCTs to maintain research progress.
Main Methods:
- Review of existing literature on adjuvant therapies and clinical trial methodologies.
- Analysis of the limitations and potential biases associated with using observational data.
- Examination of the validity and application of surrogate markers, such as pathological complete remission.
- Discussion of strategies for simplifying RCTs without compromising scientific rigor.
Main Results:
- While adjuvant therapies have improved outcomes, lower event rates complicate traditional RCTs.
- Reliance on observational data may introduce biases and inaccuracies in treatment effect estimation.
- Surrogate markers like pathological complete remission can accelerate progress but require careful validation.
- The complexity, cost, and time associated with large RCTs are significant barriers.
Conclusions:
- There is a critical need to balance the benefits of improved patient outcomes with the practical challenges of clinical trial design.
- Careful consideration of the limitations of observational data and surrogate markers is essential.
- Simplifying the conduct of RCTs is necessary to ensure continued progress in early breast cancer research.
- Further research into efficient and reliable trial methodologies is warranted.